Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

1 . A method of treating a human cancer patient comprising the step of administering to said patient an anti-cancer composition of matter comprising harmaline and a compound of the structure 
       
         
           
           
               
               
           
         
       
       where Q9 is a C3 aldehyde, and Q10 and Q11 are both H, the ratio of said harmaline to said compound being from about 0.5:1 to 15:1, said compound being present at a level of from about 25-95% by weight, and said harmaline being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight. 
     
     
         2 . The composition of  claim 1 , said composition consisting essentially of harmaline and said compound having the structure set forth in  claim 1 . 
     
     
         3 . The composition of  claim 1 , wherein at least one of said harmaline and said compound having the structures set forth in  claim 1  is in the form of an ester, metal complex, or pharmaceutically acceptable salt. 
     
     
         4 . A method of treating a human cancer patient comprising the step of administering to said patient an anti-cancer composition prepared by a method comprising the step of mixing together harmaline and a compound of the structure 
       
         
           
           
               
               
           
         
       
       where Q9 is a C3 aldehyde, and Q10 and Q11 are both H, the ratio of said harmaline to said compound being from about 0.5:1 to 15:1, said compound being present at a level of from about 25-95% by weight, and said harmaline being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight. 
     
     
         5 . The method of  claim 4 , said preparative method further including the step of mixing said harmaline and said compound as set forth in the structure of  claim 4  in ethanol, and sonicating the mixture. 
     
     
         6 . The method of  claim 4 , wherein, in said preparative method, at least one of said harmaline and said compound having the structures set forth in  claim 4  is in the form of an ester, metal complex, or pharmaceutically acceptable salt.